Aurealis Therapeutics, a Swiss-Finnish Cell and Gene Therapy Platform Company, has announced it has raised $50.0 million in new funding. This significant investment will support the advancement of its multi-target cell and gene therapy platform, which utilizes genetically modified lactic acid bacteria to address critical unmet medical needs in chronic wounds, deadly cancers, and inflammation.
The company's lead clinical product, AUP-16, targets chronic wounds such as Diabetic Foot Ulcers (DFU), Venous Ulcers, and Pressure Ulcers. Aurealis Therapeutics successfully completed a Phase 1 clinical study for AUP-16 in DFU patients, and its Phase 2 study is currently ongoing across Italy, Germany, and Poland. The company plans to expand its clinical focus to include Venous Ulcers and other types of ulcers in the future. In oncology, Aurealis is developing AUP-55, an oncolytic bacteria lead candidate, which has demonstrated promising preclinical data showing increased survival in models of Ovarian Cancer and peritoneal carcinomatosis. Its pipeline also includes early-stage programs in inflammation.
This capital infusion is intended to accelerate the clinical development of Aurealis Therapeutics' lead programs, particularly the ongoing Phase 2 study for AUP-16, and to further advance its oncology pipeline. The funds will also support the expansion of its platform technology and the exploration of new therapeutic applications. This funding round underscores investor confidence in the company's innovative approach and its potential to deliver transformative therapies.
Aurealis Therapeutics plans to leverage this investment to drive its growth initiatives, expand its research and development efforts, and ultimately bring its novel cell and gene therapies closer to patients suffering from severe and life-threatening conditions. The company is focused on continuing its clinical progress and expanding its therapeutic reach to address a broader spectrum of medical challenges.
